Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Fluidigm Technology Used to Validate New Risk Loci for Graves Disease

Published: Friday, October 07, 2011
Last Updated: Friday, October 07, 2011
Bookmark and Share
Rujin Hospital in Shanghai uses company's IFCs to validate two new susceptibility loci.

Fluidigm Corporation has announced that Rujin Hospital in Shanghai, China has used the company's integrated fluidic circuits (IFCs) to help validate two new susceptibility loci for Graves' disease.

Researchers applied the unique properties of the Fluidigm 96.96 Dynamic Array™ IFC and the EP1™ System to re-genotype selected SNPs for the replication study.

In a paper entitled A genome-wide association study identifies two new risk loci for Graves' disease, published in the August 14, 2011 issue of Nature Genetics Magazine, researchers confirmed four previously reported loci and identified two new susceptibility loci for Graves' disease.

Graves' disease is a common autoimmune disorder characterized by thyroid stimulating hormone receptor autoantibodies and hyperthyroidism.

To investigate the genetic architecture of Graves' disease, Rujin Hospital researchers conducted a genome-wide association study in 1,536 individuals with Graves' disease (cases) and 1,516 controls.

They further evaluated a group of associated SNPs in a second set of 3,994 cases and 3,510 controls. All samples were recruited from the Chinese Han population through collaboration with hospitals in China.

"The Fluidigm EP1 microfluidic genetic analysis system proved to be a powerful tool for SNP genotyping validation research in our GWAS project," noted Dr. Chun-Ming Pan of the State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine.

"The EP1 enabled us to easily set up 9,216 PCR experiments at a time without using a robot. Within four hours we acquired almost 10,000 data points with outstanding reproducibility and accuracy. The nanoliter-level reaction chambers of Fluidigm chips resulted in significant cost savings, as we needed to only use minute amounts of the expensive SNP genotyping reagents. For us, the EP1 is an ideal platform for our GWAS research," concluded Dr. Pan.

"There is world-class science being conducted in China and Rujin Hospital's important work in Graves' disease research is a great example of it," said Gajus Worthington, Fluidigm president and chief executive officer.

Worthington continued, "Fluidigm is proud to have contributed to their discoveries through the use of our genotyping systems, and there is more to come. We now have more than a dozen systems in use within China, at some of the country's leading research laboratories. We believe this is just the beginning and that our technology can play a significant and broad role in enabling China's life science researchers."

GWAS was performed on a microarray system at the Chinese National Human Genome Center in Shanghai, China. In stage 2, 100 SNPs were selected for the replication study.

Among them, 96 SNPs were genotyped using TaqMan™ SNP Genotyping Assays using the Fluidigm 96.96 Dynamic Array IFC and EP1 platform.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Revealing the Role of “Precocious” Dendritic Cells in Inflammatory Response
Discovery makes it possible for researchers to explore how these “precocious” cells escalate the body’s immune response when the body is under attack.
Monday, July 07, 2014
Singapore Single-Cell Research Centre Opens Door for Asian Biological Discoveries
Centre dedicated to diagnosis and treatment derived from single-cell exploration.
Monday, April 29, 2013
Fluidigm Announces $60 Million Public Offering of Common Stock
Company has closed the previously announced underwritten public offering of 4,209,000 shares of its common stock at a price to the public of $14.25 per share for gross proceeds of approximately $60 million.
Wednesday, August 22, 2012
Fluidigm Announces Unrestricted Sales into Prenatal Health
Fluidigm collaboration ends.
Tuesday, June 19, 2012
New Research Center to Focus on Mammalian Single Cell Genomics
New Center will feature a complete suite of Fluidigm single-cell tools, protocols and technologies.
Friday, June 15, 2012
Fluidigm Reports Financial Results for First Quarter 2012
Q1 total revenue up 26% compared to Q1 2011.
Monday, May 14, 2012
Leading Leukemia Lab Invests In Fluidigm Access Array™ and EP1™ Systems
Fluidigm Corporation has announced that MLL Munich Leukemia Laboratory (www.mll.com) has purchased Access Array™ and EP1™ Systems.
Tuesday, November 16, 2010
Research Newsletter for Biochip User Community
Fluidigm announces availability of the Fall 2010 edition of its community newsletter.
Tuesday, October 19, 2010
Fluidigm Europe Announces a new Technical Poster Describing its Access Array™ Chip Technology
New poster describes how Access Array™ chip technology has been used at NCI’s core facility to capture and sequence the entire EBV genome.
Friday, August 13, 2010
Modelling the Genetic Circuitry of Cell-to-Cell Communication
Stanford researchers used Fluidigm support instrumentation for analysis and modeling on how biological systems operate at the cellular level.
Thursday, July 15, 2010
Fluidigm Announces Availability of its Summer 2010 Edition of ‘IFC Application Hotspot’ E-newsletter
Issue includes two customer application studies, a recorded video interview with the GIS and a new single-cell gene expression protocol.
Friday, July 09, 2010
Fred Walder Joins Fluidigm as Chief Business Officer
Senior Executive from Fortune 500 company to lead business development and marketing for integrated fluidic circuit inventor.
Wednesday, June 30, 2010
Pathway-Focused Gene Expression Panels Validated for Real-time PCR
Fluidigm and SABiosciences team up to create gene expression panels validated for real-time PCR analysis on the Fluidigm BioMark™ System.
Thursday, April 08, 2010
Fluidigm and Bayer Cropscience Enter Global Agreement for Marker-Assisted Breeding and Quality Control
Fluidigm to supply integrated fluidic circuits and instrumentation to Bayer CropScience's global operations under the multi-year agreement.
Friday, February 19, 2010
Fluidigm and Bayer Cropscience Enter Global Agreement for Marker-Assisted Breeding and Quality Control
Multi-Year Supply Agreement to Drive High-Quality Seed Supply
Thursday, January 28, 2010
Scientific News
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Futuristic Brain Probe Allows for Wireless Control of Neurons
NIH-funded scientists developed an ultra-thin, minimally invasive device for controlling brain cells with drugs and light.
Microfluidic Device Mixes And Matches DNA For Synthetic Biology
Researchers have developed a microfluidic device that quickly builds packages of DNA and delivers them into bacteria or yeast for further testing.
Artificial Pancreas Controls Diabetes
Scientists are reporting the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar, or glucose, level and can automatically release insulin as needed.
Major Step for Implantable Drug-Delivery Device
MIT spinout signs deal to commercialize microchips that release therapeutics inside the body.
Smart Insulin Patch Could Replace Painful Injections for Diabetes
A joint effort between diabetes doctors and biomedical engineers could revolutionize how people with diabetes keep their blood sugar levels in check.
The Secrets of Secretion
Researchers have hacked nature's blueprints to create a new technology that could have broad-reaching impact on drug delivery systems and self-healing and anti-fouling materials.
New Tool on Horizon for Surgeons Treating Cancer Patients
Surgeons could know while their patients are still on the operating table if a tissue is cancerous, according to researchers.
Heartbeat on a Chip Could Improve Pharmaceutical Tests
A gravity-powered chip that can mimic a human heartbeat outside the body could advance pharmaceutical testing and open new possibilities in cell culture because it can mimic fundamental physical rhythms.
Unravelling the Mysteries of Carbonic Acid
Researchers have shown how gaseous carbon dioxide molecules are solvated by water to initiate the proton transfer chemistry that produces carbonic acid and bicarbonate.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!